Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents
First Claim
Patent Images
1. A method of delivering a therapeutic or diagnostic/investigational agent across the blood brain baffler (BBB) into the central nervous system in a subject in need thereof, said method comprising:
- administering to said subject a chimeric RAP fusion protein comprising said therapeutic or diagnostic/investigational agent, wherein the RAP portion of the chimeric RAP fusion protein consists of an amino acid sequence at least 80% identical to amino acids 221-323 of SEQ ID NO;
1.
9 Assignments
0 Petitions
Accused Products
Abstract
This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage diseases.
-
Citations
12 Claims
-
1. A method of delivering a therapeutic or diagnostic/investigational agent across the blood brain baffler (BBB) into the central nervous system in a subject in need thereof, said method comprising:
administering to said subject a chimeric RAP fusion protein comprising said therapeutic or diagnostic/investigational agent, wherein the RAP portion of the chimeric RAP fusion protein consists of an amino acid sequence at least 80% identical to amino acids 221-323 of SEQ ID NO;
1.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
12. A method of delivering a therapeutic or diagnostic/investigational agent across the blood brain barrier (BBB) into the central nervous system in a subject in need thereof, said method comprising:
administering to said subject a chimeric RAP fusion protein comprising said therapeutic or diagnostic/investigational agent, wherein the RAP portion of the chimeric RAP fusion protein consists of a RAP fragment of 50 to 103 consecutive amino acids within residues 221-323 of SEQ ID NO;
1.
Specification